- Conditions
- Lung Cancer
- Interventions
- Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Anaheim, California • Wichita, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 1,005
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Penpulimab, placebo
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- odetiglucan, CDX-1140
- Biological
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Interventions
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
- Conditions
- Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Monterey, California • Orange, California + 19 more
- Conditions
- Gastric Cancer, Adenocarcinoma
- Interventions
- ramucirumab, Placebo, Best Supportive Care (BSC)
- Biological · Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 14
- States / cities
- Bakersfield, California • La Jolla, California • Redlands, California + 11 more
- Conditions
- Head and Neck Cancer, Squamous Cell Cancer
- Interventions
- zalutumumab, cisplatin, Radiotherapy
- Drug · Procedure
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lung Cancer, Small Cell
- Interventions
- topotecan, carboplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Concord, California • Sacramento, California + 9 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, c-MET
- Interventions
- Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 18
- States / cities
- Chandler, Arizona • Duarte, California • Irvine, California + 15 more
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer
- Interventions
- Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more
- Conditions
- LBCL, Comprehensive Genomic, Precision Treatment
- Interventions
- Standard of Care (SOC)
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Breast Neoplasms, Male, Carcinoma, Ductal
- Interventions
- pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abraxane, Carboplatin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- None (Observational Study)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 40
- States / cities
- Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma, Locally Advanced Thyroid Gland Papillary Carcinoma, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Poorly Differentiated Thyroid Gland Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Poorly Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Oncocytic Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Follicular Carcinoma AJCC v8, Stage III Thyroid Gland Papillary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Follicular Carcinoma AJCC v8, Stage IV Thyroid Gland Papillary Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging, Zanzalintinib
- Procedure · Other · Drug
- Lead sponsor
- Jochen Lorch
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Torrance, California • Chicago, Illinois
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib in combination with pembrolizumab, Loco-regional therapy
- Drug · Procedure
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 62 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Taxoprexin, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- FKB238 (bevacizumab), Avastin (bevacizumab), Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Centus Biotherapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 11
- States / cities
- Fountain Valley, California • Whittier, California • Jacksonville, Florida + 7 more
- Conditions
- Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
- Interventions
- Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
- Drug
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more
- Conditions
- Non-Small-Cell Lung Carcinoma, Liver Cancer, Adrenal Cancer
- Interventions
- stereotactic body radiation therapy
- Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Wilmington, North Carolina • Winston-Salem, North Carolina
- Conditions
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 14
- States / cities
- La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more